Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00673387 · ClinicalTrials.gov registry record · Phase 2
Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 636
- Enrollment target
NCT00673387 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 636 participants.
The verdict
NCT00673387, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 636 participants
- Enrollment target
Study Summary
A randomized, double-blind, placebo-controlled, dose-ranging study to examine the safety, tolerability and effect on body weight of a range of doses of metreleptin and pramlintide, each administered by a separate subcutaneous (SC) injection in obese and overweight subjects.
Interventions
- DRUG metreleptin
- DRUG pramlintide acetate
- DRUG placebo-P
- DRUG placebo-M
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 636 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00673387
The ClinicalTrials.gov registry entry for NCT00673387 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 636 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which metreleptin is the first listed.
NCT00673387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00673387 about?
NCT00673387 is a clinical study titled "Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects". A randomized, double-blind, placebo-controlled, dose-ranging study to examine the safety, tolerability and effect on body weight of a range of doses of metreleptin and pramlintide, each administered by a separate subcutaneous (SC) injection in obese and overweight subjects.
What is the current status of trial NCT00673387?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 636 participants. The study started on 2008-04. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00673387?
The interventions under investigation include: metreleptin (DRUG), pramlintide acetate (DRUG), placebo-P (DRUG), placebo-M (DRUG).
Who is sponsoring clinical trial NCT00673387?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.